Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levodopa in EArly Parkinson's disease: A prospective, randomized, double blind, placebo-controlled, delayed start trial

Next Previous
Trial Profile

Levodopa in EArly Parkinson's disease: A prospective, randomized, double blind, placebo-controlled, delayed start trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms LEAP

Most Recent Events

  • 16 Sep 2020 Results of post-hoc analyses presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
  • 24 Jan 2019 Primary endpoint has not been met. (Difference in the mean total Unified Parkinsons Disease Rating Scale (UPDRS) scores between the early and delayed groups at 80 weeks)
  • 24 Jan 2019 Results (n=446) published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top